Advancements in Dalpiciclib for the Treatment of Breast Cancer Patients: A Review
Zhimin Chen,1,2 Pengjun Xie,1,2 Qihai Chen,1,2 Jie Ouyang1– 3 1The First Clinical Medical College of Guangdong Medical University, Zhanjiang, People’s Republic of China; 2Department of Breast Surgery, Dongguan Dungwah Hospital, Dongguan, People’s Republic of China; 3Dongguan Key Laboratory of Breast...
Saved in:
| Main Authors: | Chen Z, Xie P, Chen Q, Ouyang J |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-06-01
|
| Series: | Breast Cancer: Targets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/advancements-in-dalpiciclib-for-the-treatment-of-breast-cancer-patient-peer-reviewed-fulltext-article-BCTT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of first-line CDK4/6 inhibitors plus AI therapy for patients with HR +/HER2- advanced breast cancer: a network meta-analysis
by: Yanrong Kang, et al.
Published: (2025-05-01) -
A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer
by: Jialin Zhang, et al.
Published: (2025-03-01) -
Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study
by: Yu Zhang, et al.
Published: (2025-07-01) -
CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
by: Eric Raspé, et al.
Published: (2017-05-01) -
Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China
by: Benlong Yang, et al.
Published: (2025-05-01)